SERVIFY
5.8.2021 07:32:13 CEST | Business Wire | Press release
Servify , a leading provider of Extended Care and Product Protection solutions using its global, AI-enabled, digital platform, has announced hiring of senior leaders across regions and functions to drive its global expansion. Arun Verma, MS Kalsi, Kevin Cundiff, Edward Lee, Swetha Prashant, Peter Duesing, Sanghoon (Sam) Kwon, Hussein Hussein and Sergey Odinets have all been hired to bolster various verticals and regions within the organisation.
Arun Verma, with more than 20 years of experience, was appointed as the Chief Human Resources Officer . He has championed impressive success in people management across distinctly diverse industries such as Technology & Services, Finance, Management Consulting & FMCG. He worked as CHRO and Head of Administration of Beetel before Servify, and with the likes of Xerox India, McKinsey & Co., Reliance Capital Limited, and CavinKare in the past.
Makhan Singh Kalsi, also known as M S Kalsi, joins Servify as its Chief Service Officer after previously serving as the Chief Operations Officer for Digicare, a Quess Group Company. During his three years there, he scaled their operations multi-fold, with his enviable brand relationships and market reputation. He has also worked with LeEco, Samsung, Nokia, Canon, and Network Ltd in the past in various senior management positions.
Swetha Prashant joined Servify as Group General Counsel and shall be working closely with the leadership team to help scale and reinforce Servify’s legal capabilities. Swetha, a former partner of J. Sagar Associates (a leading law firm), has been practising law for more than 14 years with extensive experience in representing and advising both domestic and international clients in relation to cross border investments, M&A, JVs, private equity / venture capital, and general corporate commercial transactions and compliances across diverse sectors.
Kevin Cundiff joins Servify’s North American operations as Vice President, Partners & Account Management, and will manage all key partner relations. He has led teams responsible for product placement as well as client acquisition, development and retention in his previous roles and manage all key account relationships in North America. In the past, he has worked in senior positions at Penumbra Brands, uBreakiFix (acquired by Asurion), Fortegra (ProtectCELL parent company) and T-Mobile.
Edward Lee is an insurance industry veteran with a career spanning more than 20 years spearheaded market expansion, product development and regulatory compliance initiatives in support of global manufacturers, distributors and automotive dealer groups in both Canada and the United States for organisations such as Microsoft Corporation, CNH Industrial N.V., SquareTrade, HomeServe USA, Sears, General Motors Corp., Volvo North America, etc. He joins Servify as Vice President and Head of Insurance for North America and will also drive regulatory compliance in the warranty practice globally for Servify.
Sanghoon (Sam) Kwon joined Servify as a Senior Director and will manage Samsung as an OEM account for Servify. He comes with a rich experience which ranges from strategy building to managing global and regional businesses. He worked with Samsung Electronics in Korea and in other geographies in the past & Bolttech just before joining Servify. He is based in Seoul, South Korea.
The Technology function also sees addition of two key hires.
Dr. Peter Duesing, who became part of Servify after its acquisition of German based WebToGo, takes over the position of Vice President - Technology based out of Munich, Germany. He is now responsible for leading engineering teams for our Diagnostics and R&D functions and will also lead our patent portfolio expansion initiatives.
Ghanshyam Varindani joins Servify as Senior Director to lead the Data Engineering function. In previous roles, he has worked in senior roles at AirAsia in Malaysia and TCS leading Data Analytics Strategy and the Business Intelligence Roadmaps.
Additionally, to manage business operations in The Kingdom of Saudi Arabia & Russia, Hussein Hussein and Sergey Odinets have been respectively appointed as Regional Heads. They both have more than a decade of experience each working for top global brands.
“We are fortunate to build a global business that’s also growing massively. I am extremely proud to have these reputed leaders joining me to realise our vision. It’s always great people building great companies, and I am happy that getting great people hasn’t been a problem ever for us,” said Sreevathsa Prabhakar, Founder of Servify, on the expansion of global teams.
About Servify
Servify integrates multiple OEM Brands and their sales and service ecosystem through its product lifecycle management platform, to deliver great after-sales service experience. Started in 2015, India Headquartered Servify has spread its reach in multiple countries across the globe, partnering with over 75 OEM brands including top mobile device brands, retailers, distributors, insurers, service providers and carriers. The Servify platform processes more than 3 million transactions monthly, with 250k+ Platform users spread across retailers, service centres, contact centres and administration teams worldwide serving millions of consumers.
Additional information on Servify is available at www.servify.tech
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005106/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
